Live Analyst Rating Changes 8778 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daniel Brennan
TD
Daniel Brennan
Wall Street Analyst
★★★☆☆
#804
on 13Foresight · ranked by our own returns
56%
Success Rate
+9.0%
Average Return
31 of 55 calls profitable · +8.7% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 56% of Daniel Brennan's ratings turned a profit when each position was held for 1 year — averaging +9.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

147 Buy 69 Hold 0 Sell
Daniel's Stock Coverage 41 ratings · 2026-07-16
Company Date Position Consensus Price Target 1-Yr Return
ALMR
Alamar Biosciences, Inc.
Jul 15, 2026 BUY Strong Buy
+17.6% avg upside
5 analysts
$34.00
29.11% Upside
·
QGEN
Qiagen
Jul 15, 2026 HOLD Buy
+0.9% avg upside
24 analysts
$44.00
5.65% Upside
·
RVTY
Revvity
Jul 15, 2026 BUY Buy
-4.2% avg upside
23 analysts
$130.00
16.94% Upside
-0.3%
ILMN
Illumina
Jul 15, 2026 HOLD Buy
-16.1% avg upside
30 analysts
$192.00
3.40% Upside
+0.6%
BRKR
Bruker
Jul 15, 2026 HOLD Buy
-3.5% avg upside
22 analysts
$60.00
1.44% Upside
·
TEM
Tempus AI, Inc. Class A
Jul 15, 2026 BUY Strong Buy
+17.0% avg upside
20 analysts
$71.00
24.58% Upside
-5.0%
GRAL
GRAIL Inc
Jul 15, 2026 BUY Buy
-7.5% avg upside
8 analysts
$88.00
18.38% Upside
+0.0%
WGS
GeneDx Holdings
Jul 15, 2026 BUY Strong Buy
+17.3% avg upside
9 analysts
$85.00
32.66% Upside
+0.0%
TXG
10x Genomics
Jul 15, 2026 HOLD Buy
-29.4% avg upside
18 analysts
$47.00
3.05% Upside
+0.0%
ADPT
Adaptive Biotechnologies
Jul 15, 2026 BUY Strong Buy
-3.0% avg upside
14 analysts
$25.00
13.04% Upside
·
PSNL
Personalis
Jul 15, 2026 BUY Strong Buy
-14.3% avg upside
11 analysts
$18.00
17.24% Upside
·
AVTR
Avantor
Jul 15, 2026 HOLD Buy
+29.5% avg upside
26 analysts
$11.00
3.11% Downside
+0.0%
GH
Guardant Health
Jul 15, 2026 BUY Strong Buy
-9.5% avg upside
31 analysts
$200.00
22.33% Upside
+0.0%
NTRA
Natera
Jul 15, 2026 BUY Strong Buy
-4.0% avg upside
26 analysts
$325.00
17.76% Upside
+0.0%
NEO
NeoGenomics
Jul 15, 2026 BUY Strong Buy
+12.1% avg upside
17 analysts
$19.00
32.68% Upside
·
WAT
Waters
Jul 15, 2026 HOLD Strong Buy
+1.0% avg upside
30 analysts
$408.00
7.96% Upside
+0.6%
A
Agilent
May 27, 2026 BUY Strong Buy
+10.0% avg upside
33 analysts
$155.00
14.51% Upside
+16.6%
TMO
Thermo Fisher
May 20, 2026 BUY Strong Buy
+9.8% avg upside
38 analysts
+19.0%
MDXH
MDxHealth
May 14, 2026 BUY Strong Buy
+1387.4% avg upside
8 analysts
$1.50
259.70% Upside
-55.4%
XGN
Exagen
May 11, 2026 BUY Strong Buy
+179.3% avg upside
10 analysts
$8.00
85.18% Upside
-8.5%
CAI
Caris Life Sciences, Inc.
May 08, 2026 BUY Strong Buy
+59.8% avg upside
20 analysts
$31.00
81.31% Upside
+5.2%
PACB
Pacific Biosciences
May 08, 2026 BUY Buy
+188.3% avg upside
14 analysts
$3.00
94.87% Upside
+7.1%
QTRX
Quanterix
May 06, 2026 HOLD Buy
+352.5% avg upside
8 analysts
$4.00
1.90% Downside
+21.9%
SERA
Sera Prognostics
May 06, 2026 BUY Strong Buy
+253.6% avg upside
7 analysts
+12.7%
SOPH
SOPHiA GENETICS
May 05, 2026 BUY Strong Buy
+66.4% avg upside
7 analysts
+7.3%
BDSX
Biodesix
May 05, 2026 BUY Strong Buy
+53.8% avg upside
8 analysts
$30.00
43.90% Upside
-0.9%
NAUT
Nautilus Biotechnolgy
Apr 28, 2026 BUY Strong Buy
+560.9% avg upside
5 analysts
-32.4%
DHR
Danaher
Apr 21, 2026 BUY Strong Buy
+7.7% avg upside
45 analysts
$240.00
19.05% Upside
+2.5%
SEER
Seer
Feb 26, 2026 BUY Strong Buy
+424.7% avg upside
5 analysts
+3.9%
MYGN
Myriad Genetics
Feb 23, 2026 HOLD Hold
+194.3% avg upside
24 analysts
$7.00
11.73% Upside
+37.9%
BDX
Becton Dickinson
Jul 14, 2025 HOLD Buy
+26.5% avg upside
25 analysts
$183.00
17.69% Upside
+10.9%
LAB
Standard BioTools
May 06, 2025 BUY Buy
+633.3% avg upside
8 analysts
$2.50
194.06% Upside
-8.5%
LULU
Lululemon Athletica
Apr 27, 2023 BUY Buy
+77.0% avg upside
45 analysts
$525.00
348.02% Upside
-3.5%
VZ
Verizon
Apr 26, 2023 BUY Buy
+16.8% avg upside
40 analysts
$45.00
5.03% Upside
+15.5%
MRVI
Maravai Lifesciences Holdings
Oct 15, 2021 BUY Strong Buy
+111.5% avg upside
17 analysts
$62.00
822.70% Upside
-48.0%
TWST
Twist Bioscience
Oct 14, 2021 BUY Strong Buy
-16.7% avg upside
14 analysts
-75.0%
CRL
Charles River Labs
Aug 17, 2021 BUY Strong Buy
-7.9% avg upside
34 analysts
$465.00
101.73% Upside
-47.3%
MTD
Mettler-Toledo
May 07, 2021 SELL Buy
-11.0% avg upside
18 analysts
$1139.00
13.93% Downside
-2.9%
IQV
IQVIA Holdings
Apr 23, 2021 BUY Strong Buy
+8.9% avg upside
38 analysts
$275.00
31.90% Upside
-1.8%
ICLR
Icon
Mar 01, 2021 BUY Strong Buy
+9.7% avg upside
25 analysts
$232.00
37.30% Upside
+33.7%
VCYT
Veracyte
Nov 26, 2013 BUY Strong Buy
-14.3% avg upside
18 analysts
$16.00
72.59% Downside
-48.4%
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Daniel Brennan — Frequently Asked Questions
How accurate are Daniel Brennan's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Daniel's ratings were profitable over a one-year hold, with an average return of +9.4% per rating, or +8.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Daniel ranked on 13Foresight?
Daniel Brennan is currently ranked #804 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daniel cover?
Daniel most recently has ratings on ALMR, QGEN, RVTY, ILMN, BRKR, TEM, GRAL, WGS, TXG, ADPT, PSNL, AVTR and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.